home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2836.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
44 lines
Document 2836
DOCN M94A2836
TI Zidovudine or zidovudine/acyclovir in patients with asymptomatic HIV
infection and CD4+ cell counts greater than 400/microL.
DT 9412
AU Jahn S; Busch HW; Reichelt D; Christensen S; Zidek W; Department of
Medicine, WWU Munster, Germany.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):213 (abstract no. PB0280). Unique
Identifier : AIDSLINE ICA10/94369739
AB OBJECTIVE: We have reported earlier that a combination therapy with
zidovudine and acyclovir reduces the frequency of herpesvirus infections
in patients with severe HIV-disease. 1. To determine the frequencies of
herpesvirus infections (HSV, VZV, EBV) 2. The progression of clinical
HIV-disease, development of AIDS or severe AIDS-related complex and 3.
CD4+ cell count less than 350/microliters in patients with asymptomatic
HIV-infection and CD4+ greater than 400/microliters in patients which
received either AZT 500 mg/d or AZT 500/ACV 800 mg/d. METHODS: We
analyzed the data of 165 patients over a period of 48 months. 85
patients received AZT 500 mg/d and 80 patients received AZT 500 mg/ACV
800 mg/d. Data were analyzed by survival methods, including Kaplan-Meier
estimates and log-rank tests. RESULTS: Patients which received AZT
500/ACV 800 mg/d developed significant less herpesvirus infections (HSV,
VZV, EBV) than patients which received AZT 500 mg/d alone and showed
significant more seldom a progression of clinical HIV-disease,
development of AIDS or severe AIDS-related complex and a CD4+ cell count
less than 350/mu. DISCUSSION AND CONCLUSIONS: Because of the reduction
of herpesvirus infections (HSV, VZV, EBV), of disease progression and a
CD4+ cell count less than 350/microliters it seems to be useful to offer
all patients with asymptomatic HIV-infection and CD4+ cell counts
greater than 400/microliters a combination therapy with AZT 500 mg/d and
Acyclovir 800 mg/d.
DE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL
Acyclovir/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE AIDS-Related
Opportunistic Infections/EPIDEMIOLOGY/PREVENTION & CONTROL Comparative
Study Drug Therapy, Combination Herpesviridae
Infections/EPIDEMIOLOGY/PREVENTION & CONTROL Human HIV
Infections/*DRUG THERAPY/MORTALITY Leukocyte Count Life Tables
Survival Analysis Treatment Outcome T4 Lymphocytes
Zidovudine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).